About Manipal Health Enterprises
Manipal Health Enterprises (MHE) is one of India's top three private hospital chains by bed count, operating over 9,000 beds across 30+ hospitals in India and internationally. The Bangalore-headquartered group is backed by TPG Capital, which acquired a majority stake in 2015, and has grown significantly through both organic expansion and acquisitions (notably the AMRI Hospitals acquisition in 2022).
Manipal's hospitals are particularly strong in South India (the flagship Manipal Hospital in Bangalore is a landmark institution) and the company has built a reputation for tertiary and quaternary care — complex procedures that command premium pricing and are less susceptible to commoditisation than primary care.
The Hospital Sector Investment Case
Private hospital chains are one of the most compelling long-term investment themes in India:
- Structural underpenetration: India has approximately 1.3 hospital beds per 1,000 people vs 3+ in developed economies. This gap will close over the next decade, driving consistent demand for new beds.
- Healthcare spending growth: India's healthcare spending as a percentage of GDP has been rising, and private health insurance penetration is growing — increasing the addressable market for quality private hospitals.
- Premium care demand: A growing affluent class is willing to pay for better facilities, shorter waiting times, and access to specialised treatments not available in public hospitals.
- Medical tourism: India's cost advantage in complex medical procedures attracts patients from Southeast Asia, Africa, and the Middle East — a high-value revenue stream for top-tier hospital chains.
Valuation Framework for Hospital Chains
Hospital companies are typically valued on EV/EBITDA (given capital intensity and depreciation variability) and EV/Bed (total enterprise value divided by operational bed count). Comparable listed peers include Apollo Hospitals (premium-valued, the sector benchmark), Fortis Healthcare, NH (Narayana Health), and Aster DM Healthcare. Manipal's valuation relative to these peers will be the key pricing signal when the price band is announced.
GMP Expectations and How to Evaluate
Healthcare sector IPOs in India have consistently generated positive GMP given the strong secular growth story and institutional investor demand for quality healthcare exposure. Manipal Health's scale, brand, and TPG backing make it a high-credibility IPO. The key variable will be the price band — if priced at a discount to Apollo's multiples, GMP could be substantial. Monitor Manipal Health IPO GMP on GMPIpoWatch once subscription dates are announced.
Loading comments...